JP2022553464A5 - - Google Patents

Info

Publication number
JP2022553464A5
JP2022553464A5 JP2021537127A JP2021537127A JP2022553464A5 JP 2022553464 A5 JP2022553464 A5 JP 2022553464A5 JP 2021537127 A JP2021537127 A JP 2021537127A JP 2021537127 A JP2021537127 A JP 2021537127A JP 2022553464 A5 JP2022553464 A5 JP 2022553464A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
peptide linker
cancer
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553464A (ja
Filing date
Publication date
Priority claimed from CN201911015236.1A external-priority patent/CN110669137B/zh
Application filed filed Critical
Publication of JP2022553464A publication Critical patent/JP2022553464A/ja
Publication of JP2022553464A5 publication Critical patent/JP2022553464A5/ja
Priority to JP2025088503A priority Critical patent/JP2025143248A/ja
Pending legal-status Critical Current

Links

JP2021537127A 2019-10-24 2020-07-08 多重特異性抗体とその製造方法および使用 Pending JP2022553464A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025088503A JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911015236.1A CN110669137B (zh) 2019-10-24 2019-10-24 一种多特异性抗体及其制备方法和用途
CN201911015236.1 2019-10-24
PCT/CN2020/100892 WO2021077806A1 (zh) 2019-10-24 2020-07-08 一种多特异性抗体及其制备方法和用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025088503A Division JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Publications (2)

Publication Number Publication Date
JP2022553464A JP2022553464A (ja) 2022-12-23
JP2022553464A5 true JP2022553464A5 (enExample) 2023-07-19

Family

ID=69083964

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021537127A Pending JP2022553464A (ja) 2019-10-24 2020-07-08 多重特異性抗体とその製造方法および使用
JP2025088503A Pending JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025088503A Pending JP2025143248A (ja) 2019-10-24 2025-05-28 多重特異性抗体とその製造方法および使用

Country Status (7)

Country Link
US (2) US12415852B2 (enExample)
EP (1) EP3868788A4 (enExample)
JP (2) JP2022553464A (enExample)
KR (1) KR20220087402A (enExample)
CN (2) CN110669137B (enExample)
AU (1) AU2020371001A1 (enExample)
WO (1) WO2021077806A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途
CN113214406B (zh) * 2020-01-21 2022-08-02 苏州普乐康医药科技有限公司 一种结合gpc3融合蛋白的制备方法及应用
CN112336873B (zh) 2020-08-04 2022-04-19 华南理工大学 用于多特异性抗体递送的蛋白型纳米颗粒及其应用、制备方法
CN114478788B (zh) * 2020-11-11 2025-07-18 北京免疫方舟医药科技有限公司 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
KR102618718B1 (ko) * 2021-01-11 2023-12-29 주식회사 유틸렉스 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도
CN113527503A (zh) * 2021-07-27 2021-10-22 福建医科大学 一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白
US20240417469A1 (en) * 2021-10-12 2024-12-19 Concept To Medicine Biotech Co., Ltd. Cd3-targeting t-cell engagers with improved therapeutic index
CN114409797B (zh) * 2021-12-24 2024-02-20 合肥天港免疫药物有限公司 重组抗体及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
CN114380917B (zh) * 2022-03-25 2022-06-14 南京融捷康生物科技有限公司 针对IL-17A和TNFα的双特异性单域抗体及其用途
CN115368448B (zh) * 2022-07-19 2025-08-01 合肥天港免疫药物有限公司 双特异性抗体及其应用
US20260116960A1 (en) * 2022-09-29 2026-04-30 Shanghai Hongcheng Biopharmaceutical Co., Ltd. Trispecific antibodies targeting pd-1, ctla-4 and vegf and use thereof
CN115969997B (zh) * 2022-12-19 2024-02-13 华润生物医药有限公司 一种靶向cldn18.2的抗体药物偶联物及其应用
CN116987198B (zh) * 2023-09-28 2023-12-26 军科正源（北京）药物研究有限责任公司 一种靶向人pd-l1的融合蛋白及其用途
CN117843803B (zh) * 2023-12-29 2024-11-29 北京贝来药业有限公司 串联单域抗体及其在疾病治疗中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
WO1992022324A1 (en) * 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
CN100497390C (zh) * 2003-06-27 2009-06-10 比奥根艾迪克Ma公司 疏水-相互作用-层析或铰链区修饰对于均质抗体溶液的制备的用途
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
RU2531754C2 (ru) * 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
JP5522405B2 (ja) 2008-04-25 2014-06-18 協和発酵キリン株式会社 安定な多価抗体
EP2285833B1 (en) * 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
TW201138821A (en) * 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
EP2748202B1 (en) 2011-08-23 2018-07-04 Roche Glycart AG Bispecific antigen binding molecules
JP6060162B2 (ja) 2011-08-23 2017-01-11 ロシュ グリクアート アーゲー ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2015103549A1 (en) * 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
AU2015237864B2 (en) * 2014-03-24 2020-12-03 Cancer Research Technology Limited Modified antibodies containing modified IgG2 domains which elicit agonist or antagonistic properties and use thereof
MX2016014434A (es) * 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201411320D0 (en) * 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
WO2016001810A1 (en) * 2014-07-01 2016-01-07 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
CN104592392B (zh) * 2015-01-21 2018-08-28 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
EP3967755B1 (en) * 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
CN104558191B (zh) * 2015-01-21 2020-08-21 武汉友芝友生物制药有限公司 一种双特异性抗体cd20×cd3的构建及应用
GB201521393D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201522391D0 (en) * 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
SG11201809316XA (en) * 2016-04-28 2018-11-29 Biomunex Pharmaceuticals Bispecific antibodies targeting egfr and her2
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
AU2018228435C1 (en) * 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
CN107266567B (zh) * 2017-06-05 2021-06-04 高新 Lcrmp4单克隆抗体及其制备方法与应用
JP7500619B2 (ja) * 2019-05-30 2024-06-17 アムジエン・インコーポレーテツド 抗体の二量体化を促進するためのヒンジ領域の操作
CN110669137B (zh) * 2019-10-24 2021-07-16 高新 一种多特异性抗体及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2022553464A5 (enExample)
JP2025143248A (ja) 多重特異性抗体とその製造方法および使用
JP7348899B2 (ja) 多重特異性分子及びその使用
US20220288200A1 (en) Multispecific and multifunctional molecules and uses thereof
AU2018224094B2 (en) Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
CN109906232B (zh) 包含λ轻链和κ轻链的多特异性抗体分子
AU2017345791B2 (en) Multimeric IL-15-based molecules
JP7809639B2 (ja) Ｍａｉｔ及び腫瘍細胞の両方に結合する多重特異性抗体
CA3059769A1 (en) Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
JP2018537415A (ja) 多価Ｆｖ抗体
MX2014000816A (es) Molecula fv de union de antigeno multivalente.
CA3233075A1 (en) Interleukin-2 mutant and fusion protein thereof
JP2024116283A (ja) Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤
US20230295348A1 (en) Composition and methods for the selective activation of cytokine signaling pathways
EP4245774A1 (en) Fusion protein targeting both cd3 and cd137, preparation method therefor and use thereof
EA051393B1 (ru) Биспецифические связывающие агенты, связывающиеся с cldn18.2 и cd3
HK40014316A (en) Multimeric il-15-based molecules